Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target? - Wikidata - wikimedia - TriplyDB

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

http://www.wikidata.org/entity/Q33858322

about

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

http://www.wikidata.org/entity/Q33858322

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

@ast

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

@en

type

label

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

@ast

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

@en

prefLabel

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

@ast

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

@en

P1433

Q33858322-7044F93E-721A-48D0-9EE8-C3D885534FBF

P1476

Q33858322-C137FB1A-5A0F-4B96-A44E-75D64DD6C5DB

P2093

Q33858322-4D9C50B3-635E-4AC9-B248-9AB7C0E9D784

Q33858322-6ABA1CA7-2CE4-40BE-9BCA-BD4D61BBE680

Q33858322-7EFEF01E-C332-4610-83EA-E4432A778467

Q33858322-CBAE8EE2-455D-4433-B3B5-D55F88433E5E

Q33858322-CCC5C37C-75DC-4536-A7C4-03E2942B8C50

P2860

Q33858322-031E66DF-A8C2-4DC3-88E0-7C9D56A5B779

Q33858322-057A2B20-D1A8-4583-A613-48BDE34E3C2F

Q33858322-1055C2CF-B48F-49FD-A8C8-C980C6AF989A

Q33858322-11D12180-041A-4214-A86A-E3027193E2BF

Q33858322-15993F62-01CA-40AE-B494-34502F70C70F

Q33858322-1729669D-6BF3-4D7F-A267-96361EDD4780

Q33858322-173A5AED-B281-4B6B-81D8-E3E623B42AC6

Q33858322-1FAC2F6B-292A-45D5-9255-0FE8BE283CC3

Q33858322-1FE5D5B0-20B5-43AC-9E43-AC3F8BE0BF27

Q33858322-29D22BF1-FE9C-4664-A1D9-B20533CCF529

P304

Q33858322-B859E52E-4FCA-4712-986A-660725D2809F

P31

Q33858322-7AE24634-36CB-407E-A2E7-86C6508B1E0A

P356

Q33858322-EFB05EB4-D439-4DA6-A6DF-B0AF16F27269

P478

Q33858322-C9D3E6CC-8171-45CF-8F6B-0048DDEA0667

P577

Q33858322-2AFA581B-9E96-40A7-8E2E-7AD5E7A24EE5

P698

Q33858322-450112AA-9F2A-4542-8078-A5D811E1A709

P932

Q33858322-0B333E86-7142-4889-9F83-408748ACDFE0

P356

FPHAR.2017.00437

P1433

Frontiers in Pharmacology

P1476

Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

@en

P2093

Aleksandar Miljatovic

http://www.w3.org/2001/XMLSchema#string

Dijana L Puskas

http://www.w3.org/2001/XMLSchema#string

Laslo Puskas

http://www.w3.org/2001/XMLSchema#string

Mirjana R Jovanovic

http://www.w3.org/2001/XMLSchema#string

Slobodan Kapor

http://www.w3.org/2001/XMLSchema#string

P2860

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Self-reported hepatitis C virus antibody status and risk behavior in young injectors

Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention

Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco.

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

Impact of hepatitis C virus infection on lifestyle.

P304

437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2017.00437

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28713277

http://www.w3.org/2001/XMLSchema#string

P932

5492802

http://www.w3.org/2001/XMLSchema#string